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within the epithelium and the rate of
subsequent lateral expansion. Against
these benchmarks biased stem cell
behaviors advantaged in both fixation
and expansion can be quantified to
predict the age-related burden of pro-
oncogenic mutation.
Cell Stem Cell
Short ArticleFixation and Spread of Somatic Mutations
in Adult Human Colonic Epithelium
Anna M. Nicholson,1 Cora Olpe,1,2 Alice Hoyle,1 Ann-Sofie Thorsen,1 Teja Rus,1 Mathilde Colombe´,1
Roxanne Brunton-Sim,3 Richard Kemp,1 Kate Marks,4 Phil Quirke,4 Shalini Malhotra,5 Rogier ten Hoopen,5
Ashraf Ibrahim,5 Cecilia Lindskog,6 Meagan B. Myers,7 Barbara Parsons,7 Simon Tavare´,1 Mark Wilkinson,3
Edward Morrissey,8,* and Douglas J. Winton1,9,*
1Cancer Research-UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
2Wellcome Trust-Medical Research Council, Cambridge Stem Cell Institute, Cambridge, UK
3Norwich Research Park BioRepository, James Watson Road, Norwich NR4 7UQ, UK
4Pathology and Tumour Biology, Level 4, Wellcome Trust Brenner Building, St. James University Hospital, Beckett Street, Leeds LS9 7TF, UK
5Department of Histopathology, Box 235, CUHFT, Cambridge, UK
6Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala 751 85,
Sweden
7Division of Genetic andMolecular Toxicology, National Center for Toxicological Research, US Food andDrug Administration, HFT-120, 3900
NCTR Road, Jefferson, AR 72079, USA
8MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
9Lead Contact
*Correspondence: edward.morrissey@imm.ox.ac.uk (E.M.), doug.winton@cruk.cam.ac.uk (D.J.W.)
https://doi.org/10.1016/j.stem.2018.04.020SUMMARY
We investigated the means and timing by which
mutations become fixed in the human colonic
epithelium by visualizing somatic clones and mathe-
matical inference. Fixation requires two sequential
steps. First, one of approximately seven active
stem cells residing within each colonic crypt has to
be mutated. Second, the mutated stem cell has to
replace neighbors to populate the entire crypt in a
process that takes several years. Subsequent clonal
expansion due to crypt fission is infrequent for
neutral mutations (around 0.7% of all crypts undergo
fission in a single year). Pro-oncogenic mutations
subvert both stem cell replacement to accelerate
fixation and clonal expansion by crypt fission to
achieve high mutant allele frequencies with age.
The benchmarking of these behaviors allows the
advantage associated with different gene-specific
mutations to be compared irrespective of the cellular
mechanisms by which they are conferred.
INTRODUCTION
The extent to which the cellular properties of adult stem cells
determine the risk of neoplastic transformation is currently
debated (Tomasetti and Vogelstein, 2015; Wu et al., 2016; Tom-
asetti et al., 2017). The rationale is that stem cells, oncemutated,
allow variants to become fixed and subsequently spread within
the tissue. However, the fates of individual stem cells in the
renewing epithelia most at risk of developing cancers are
stochastic (Blanpain and Fuchs, 2014). Consequently, mutation
of an individual stem cell establishes unknown probabilities for
variant fixation and the rate of lateral clonal expansion.Cell Stem Cell 22, 909–918
This is an open access article undFor colorectal cancers, the conventional view that successive
clonal sweeps populate tumors during progression has been
called into question. Regional sampling within individual cancers
has revealed that subclones are distributed throughout the can-
cer suggesting that cancers arise as a single expansion event
when a combination of factors achieves a critical threshold (Sot-
toriva et al., 2015). These new concepts make establishing the
cellular mechanisms by which somatic variants arise, become
fixed and spread within adult colonic epithelium more urgent.
To date, these processes have been considered qualitatively,
in isolation and not integrated to establish how variant burden
accumulates. Consequently, there is no benchmark against
which to compare the impact of advantaged or pro-oncogenic
mutations.
Previously by analysis of age-related changes in clone fre-
quencies we inferred the stem cell dynamics that dictate the
probability of clone fixation in mice (Kozar et al., 2013). Here,
the approach is applied to the human colonic epithelium by
detecting spontaneous gene-specific mutation. We find that
human colonic crypts are maintained by approximately seven
clonogenic stem cells of which one is replaced around once
every 9 months. Variant fixation requires all wild-type stem cells
to be displaced defining a process of monoclonal conversion of
crypts that takes many years. Subsequent expansion of neutral
clones into multiple crypts by crypt fission is a rare event in adult
life. Biased behaviors are confirmed to subvert these processes
to achieve variant over representation.RESULTS
Detection and Analysis of a Known Clonal Mark: mPAS
Few visualizable clonal marks have been described. One previ-
ously used in human colon detects loss of O-acetylation of
sialomucins using a mildly reductive periodic acid Schiff tech-
nique (mPAS) (Veh et al., 1982). mPAS staining of FFPE colon
sections from samples obtained at surgical resection confirmed, June 1, 2018 ª 2018 The Authors. Published by Elsevier Inc. 909
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
previously described staining patterns (Sugihara and Jass,
1986). These are composed of crypts that are wholly populated
(WPC) or partially populated (PPC) with mPAS+ clones and also
crypts containing single positive cells (Figures 1A–1D).
The mode of inheritance of this unknown polymorphic locus
indicates that around 90%of theWestern population are permis-
sive high O-acetylators (Fuller et al., 1990). The 10% of low-ace-
tylator homozygote individuals are readily identifiable by mPAS+
staining throughout the sample. The permissive high O-acetyla-
tors divide into 55.6% uninformative homozygotes and 44.4%
that are heterozygotes (Campbell et al., 1994). An image analysis
pipeline was developed to detect mPAS+ clones (Figure S1).
Identification and Scoring of mPAS+ Clones
Histologically normal colonic epithelium from surgically resected
samples was evaluated for mPAS detection. Of 187 patients
(Table S1), 50 ranging between 37 and 93 years of age were
informative using defined inclusion criteria. An age-related in-
crease in WPCs was observed (Figure 1E). The slope, DCfix,
describing accumulation of WPCs, was 5.85 3 106 crypts per
year (95% margin of error [ME]: ± 2.68 3 106) (Figure 1F).
Importantly, as expected there was no age-related increase in
PPC (Figure 1E), present at around 1.05 per 104 crypts (>95%
ME: ± 0.32 per 104 crypts). The de novo appearance of transi-
tion-form PPCs is balanced by their loss due either to stem cell
extinctions or expansions that generate WPCs and thereby
maintain DCfix (Kozar et al., 2013).
The rate of conversion of PPCs (Cpart) to maintain the slope of
DCfix indicates that monoclonal conversion of human colonic
crypts takes many years (13 years for 90% conversion, median
6.3 years). Notably, this is in accord with observations in patients
one year after radiation therapy that clones are predominately
PPCs and with published times to monoclonality that are of the
order of years (Campbell et al., 1996; Yatabe et al., 2001; Kim
and Shibata, 2002).
Determination of De Novo Mutation Rate
It is known that both DCfix and Cpart are dependent on the
de novo mutation rate (Kozar et al., 2013). New mutations can
be identified as clones arising in the proliferative zone above
but not connected to the crypt base. To determine the mutation
rate serial sections from nine patients were stained for mPAS.
From 232 tissue sections, containing two million crypts a total
of 60 new clones were identified (Figures 1G, 1H, and S2A).
The mutation rate is directly derived from the ratio of the
number of positive cells and the total target population (Kozar
et al., 2013); in this case, single mPAS+ cells/total goblet cells
were estimated (Figures S2B–2D). The selected patients were
representative in terms of number of mPAS+ WPC and PPCs
(Figure S2E). Variation in estimates across patients may indicate
a potential distribution of mutation rates. There was no appre-
ciable age-related trend (Figure 1I). The overall de novomutation
rate was 4.44 3 106 mutations per mitosis (>95% ME: ±
2.69 3 106).
Inference of Stem Cell Number and Replacement Rate
Combining the estimate of DCfix and Cpart for mPAS
+ clones,
together with the de novomutation rate, the values for the num-
ber of stem cells per crypt (Ncrypt) and rate of stem cell replace-910 Cell Stem Cell 22, 909–918, June 1, 2018ment (lcrypt) were calculated. This revealed that human colonic
crypts each contain between 5 and 10 active stem cells (95%
Credible Interval (CI); mean = 7). The replacement rate is
between 0.65 and 2.7 stem cell replacements/crypt/year (95%
CI; mean = 1.3) (Figure 1J). The latter estimate contrasts to the
mouse where the replacement rate is nearly 100-fold faster
(Kozar et al., 2013).
Validation using New Clonal Marks
To validate the above additional clonal marks were sought. Four
genes encoded on the X chromosome, subject to X-inactivation
and not associated with DNA repair or pro-oncogenic processes
were assessed (Table S2). Antibody staining patterns consistent
with truncating mutations were only observed for MAOA with
bothWPC and PPC crypts identified (Figures 2A and 2B). Confir-
mation of the ability to detect MAOA protein was shown using
two independent antibodies in serial sections (Figure 2A). Next,
patients were screened to assess the age-related change in
MAOA– clone frequencies (Figures 2C and 2D). As for mPAS
an age-related accumulation of WPC and constant background
frequency of the transition-form PPCs was observed (Figure 2C).
The regression revealed a DCfix of 1.76 3 10
6 per year (>95%
ME: ± 0.42 3 106) (Figure 2D).
Rates of clone fixation will vary for different clonal marks
because different loci will have different somatic mutation rates.
However, the balanced loss/replacement of stem cells that acts
to resolve PPCs and support DCfix will be identical for neutral
marks. Thus DCfix/Cpart is independent of mutation rate and
describes the dynamic that leads to monoclonal conversion.
The larger cohort of patients scored for clonal loss of MAOA
(152 patients) also contained those informative for mPAS (48).
We considered the MAOA data derived from mPAS informative
and uninformative patients separately. Reassuringly this re-
vealed that the slopes describing the age related accumulation
ofMAOA-deficient clones, the background frequencies of transi-
tion-form clones and DCfix/Cpart are near identical for the two
subgroups (Figures 2E and S3A–S3E).
Importantly, comparing pooled MAOA andmPAS data reveals
similar values for DCfix/Cpart of 7.2 3 10
2 (>95% ME: ± 2.3 3
102) and 5.63 102 (>95%ME: ± 3.23 102), respectively (Fig-
ure 2E). This shows that, despite the different mutation rates and
resultant clone frequencies, the inferred dynamics of stem cell
replacement closely correspond (Figure 2F).
Previously analysis of intra-clone size variation within 11 PPC
clones has indicated around six functional stem cells/crypt,
similar to our estimate, but also a stem cell replacement rate
around 100-fold faster than that derived here (Baker et al.,
2014). To resolve this disparity, we focused on the implications
of the different estimates on the time for crypt monoclonal con-
version. Competition between a small number of stem cells
undergoing rapid replacement will inevitably result in the popula-
tion of the crypt by a single clone in 3 weeks. This is not compat-
ible with documented times to monoclonality described for
human crypts and observed here (Figures S3F and S3G) (Camp-
bell et al., 1996; Yatabe et al., 2001; Kim and Shibata, 2002).
Further slow replacement rates will only infrequently result in
stem cell mediated changes in clone size that can be captured
due to the rapid tissue turnover of around 3–8 days (Potten
et al., 1992; Baker et al., 2014). This suggests that additional
Figure 1. Identification and Quantification of mPAS+ Clones
(A) Longitudinally sectioned sporadic mPAS+ wholly populated crypts (WPC).
(B and C) Sporadic WPC (B) and partially populated crypts (PPC) (C) within en face tissue sections.
(D) Single mPAS+ cell within a crypt.
(E) Frequencies of mPAS+ WPC (circles) and PPC (squares) plotted against patient age. Bottom panel shows PPC only on expanded y axis.
(F) Regression analysis showing DCfix plotted in red at 5.85 3 10
6 per year with 95% ME in gray.
(G) mPAS+ clones are marked within processed images in black before serial sections are aligned to enable tracking of clones.
(H) WPC (circles) and PPC (squares) can be traced through aligned serial sections (i), while de novo mutations occurring in TA cells cannot (ii).
(I) Frequency of de novomPAS+ cells derived for 9 patients plotted by age. Each bar represents a single sample, up to three samples were analyzed per patient.
The overall mutation rate (a) was calculated to be 4.44 3 106 mutations per mitoses (±2.69 3 106; ME 95%).
(J) Heatmap representing posterior probabilities for the indicated combination of functional stem cell number for crypt (N, y axis) and the rate of stem cell
replacement per year per stem cell (l, x axis). Colors represent posterior probability, white indicating a very low probability that this value underlies the actual
dynamics observed, blue indicating a high likelihood. Inference of N and l in human colonic crypts indicates between 5 and 10 (95%CI; mean = 7) functional stem
cells replacing each other at a rate of between 0.65 and 2.7 stem cell replacements per crypt per year (95% CI; mean = 1.3).
See also Figures S1 and S2.
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Figure 2. Validation of Clone Dynamics using Novel Clonal Marks
(A) Serial sections (i) and (ii) stained with different antibodies for MAOA. Negative crypt highlighted and enlarged.
(B) (i) WPC and (ii) PPC in en face tissue sections stained for MAOA.
(C) Frequency plots of WPC (circles) and PPC (squares) for MAOA– clones for 152 patients (age 8–93 years). Bottom panels show PPC frequencies alone on
expanded y axis.
(D) Regression analysis showing DCfix for MAOA (1.76 3 10
6 per year) plotted in red with 95% ME shaded in gray.
(E) Boxplot showing similar ratio for DCfix /Cpart for MAOA (7.2 ± 2.3 3 10
2) and mPAS (5.6 ± 3.2 3 102) (MAOA mPAS– [6.8 ± 2.9 3 102] and MAOA mPAS+
[8.9 ± 4.5 3 102]). >95% ME.
(F) Inferred mutant fixation times by crypt monoclonal conversion plotted using parameters derived from spontaneous mPAS+ and MAOA– clones.
See also Figure S3.processes such as variation in the number of amplifying cell
divisions and/or variation in the extent of lateral versus vertical
migration of transit amplifying cells contribute to the fluctuations
in clone size as progeny move toward the luminal surface.
Identifying Biased Behaviors
To establish whether analysis of clone dynamics has the poten-
tial to identify advantage for potentially pro-oncogenic mutations912 Cell Stem Cell 22, 909–918, June 1, 2018a further four genes (APEX2, POLA1, RBBP4, and STAG2)
encoded on the X chromosome and associated with DNA repair
or pro-oncogenic function were assessed (Table S2). Staining
consistent with clonal truncating mutations was identified for
STAG2 only (Figures 3A and 3B). This was confirmed with two
independent antibodies (Figure 3A). STAG2– WPC and PPC
were observed (Figure 3B). The former showed an age-related
increase (Figure 3C) and DCfix determined to be 1.96 3 10
5
Figure 3. Comparison of Marks Reveals Bias for STAG2 Mutation
(A) Serial sections (i) and (ii) stained with different antibodies for STAG2. Negative crypt highlighted and enlarged.
(B) (i) WPC and (ii) PPC in en face tissue sections stained for STAG2.
(C) Frequency plots of WPC (circles) and PPC (squares) for STAG2-deficient clones for 186 patients (age 8–93 years). Bottom panels show PPC frequencies only
on expanded y axis.
(D) Regression analysis showing DCfix for STAG2 (1.96 3 10
5 per year) plotted in red with 95% ME shaded in gray.
(E) Boxplot showing similar ratio forDCfix /Cpart forMAOAandmPAS (7.2 ± 2.33 10
2 and 5.6 ± 3.23 102) while STAG2 shows 103 increased ratio at (503 102;
>95% ME: ± 14 3 102).
(F) Boxplot showing DCfix (dark boxes) and Cpart (light boxes) for the three clonal marks. >95% ME.
(G) Boxplot showing the calculated mutation rate for each clonal mark. >95% ME.
(H) Histological sections showing multicrypt patches for (i) mPAS+, (ii) MAOA–, and (iii) STAG2– crypts.
(legend continued on next page)
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per year (>95%ME: ± 0.423 105) (Figure 3D). Notably the ratio
DCfix/Cpart was increased 10-fold (50 3 10
2; >95% ME: ± 14 3
102) compared to that observed for MAOA and mPAS (Fig-
ure 3E) and arises due to an under-representation of PPCs (Fig-
ure 3F), suggesting a bias in stem cell replacement. Applying the
values for Ncrypt and lcrypt determined above (7 and 1.3/year,
respectively), we estimate that this probability departs from
neutral replacement (0.5) to around 0.99 (95% CI: 0.8–0.99),
i.e., near certainty that a STAG2-deficient stem cell will populate
the crypt. Consequently, the time for monoclonal conversion is
reduced and most mutant clones become fixed.
Direct versus Indirect Effect of STAG2 Mutation
STAG2 encodes a subunit of the cohesin complex, has been
associated with aneuploidy, and is a tumor suppressor gene
(Kim et al., 2012; Hill et al., 2016). STAG2 loss results in pro-
longed association of telomeric repeats during the cell cycle
and that this may result in genomic rearrangements (Daniloski
and Smith, 2017). To explore whether the biased behavior of
STAG2-deficient stem cells arises directly or whether it could
be mediated by subsequent elevated genomic instability, we
performed simulations. These allow a first neutral mutation
(STAG2) followed by a second higher probability mutation
conferring advantage (certain to replace wild-type neighbors)
that drives the altered clone dynamics. This was compared to
the principal mathematical model, which simulates a single
altering mutation. The comparison revealed that the rate of sec-
ond mutation has to be increased by the order of 105 before all
clones contain both mutations and that even this level of hyper-
mutation fails to explain the observed age related increase in
STAG2-deficient clones (Figures S3H and S3I). To impact on
intracryptal clone dynamics secondary mutations conferring
advantage have to occur in STAG2 mutant clones while they
are still PPCs and this requires an extremely high mutation
rate. It is likely the clone dynamics described arise directly
from STAG2 loss.
Inference ofMAOA and STAG2 Mutation Rates
Using the ratio of Cpart between mPAS and MAOA and the muta-
tion rate derived for mPAS, we can estimate the mutation rate for
MAOA to be 1.03 3 106 mutations per mitosis (>95% ME:
1.03 ± 0.78 3 106). As STAG2 mutation is not neutral, we use
the full equations taking N = 7 and PR = 0.99 leading to amutation
rate for STAG2 of 1.663 106 mutations per mitosis (>95%ME:
1.66 ± 1.3 3 106) (Figure 3G). Notably the X-linked gene PIGA
that forms the basis for mutagenesis screens and that is of
similar size and intron/exon structure to MAOA has a compara-
ble mutation rate in human cells of 106/mitosis (Araten
et al., 2005).
Clonal Expansion beyond the Crypt
Colonic clones can expand beyond individual glands by crypt
fission (Greaves et al., 2006). For all three clonal marks, patches(I) Histogram showing patch sizes for mPAS, MAOA, and STAG2.
(J) Plot showing an age-associated increase in number of patches.
(K) Boxplot showing the inferred crypt fission rate for each of the clonal marks, with
0.72% (95% CI: 0.72 ± 0.15) per year. However, STAG2-deficient crypts underg
See also Figure S3.
914 Cell Stem Cell 22, 909–918, June 1, 2018of mutant epithelium comprising two or more crypts were
observed at a low frequency (Figure 3H). Patches of two were
frequently identified for mPAS+ and MAOA– marked crypts,
whereas larger patches were uncommon. Larger patches were
frequently observed for STAG2– crypts that also showed an
age-related increase (Figures 3I and 3J).
The age-related change in the patch sizes was modeled. This
revealed the crypt fission rate for mPAS+ and MAOA– crypts to
be 0.68% (95% CI: 0.68 ± 0.15) and 0.72% (95% CI: 0.72 ±
0.15) per year, respectively. STAG2-deficient crypts undergo
fission at a rate of 2.15% (95% CI: 2.15 ± 0.27) per year (Fig-
ure 3K), 3-fold that of normal fission rates and accounting for
the larger patches observed. Therefore, as well as conferring
an advantage to the stem cells within the crypt, STAG2 defi-
ciency also enables lateral expansion to generate large patches
within the epithelium.
Previous estimates for the rate of colonic crypt fission have
employed different approaches and have varied widely with
estimates ranging between 3% and 22% of crypts undergoing
fission per year (Totafurno et al., 1987; Baker et al., 2014). The
lower estimate of 0.7% derived here is consistent with other
studies documenting age-related changes in genomic methyl-
ation patterns that found no conserved patterns between
neighboring crypts, suggesting most crypts survive without un-
dergoing fission during adult life (Kim and Shibata, 2002, 2004).
Recently a crypt fusion process has been described in mouse
intestinal epithelium at a rate equivalent to that of fission (Bruens
et al., 2017). Mutant fusion has two possible outcomes. Either a
mutant crypt can fuse with another mutant crypt thereby
reducing patch size or it can fuse with a wild-type crypt in which
case the patch size could reduce or stay the same. To determine
whether fusion could impact on our interpretation of clone size
data, we used stochastic simulations to explore the effect of
different fusion rates (Figure S4). This analysis showed that the
patch size is dominated by crypt fission with fusion having a
negligible effect in comparison. This was observed for both the
neutral and advantageous mutations.
Implications for Fixation and Spread of Clonal Variants
The accumulated burden of neutral somatic variants within the
human colonic epithelium varies with the mutation rate (Fig-
ure 4A). However, selection can act either to promote fixation
of mutant clones by biased stem cell replacement and/or to pro-
mote their spread by elevated rates of crypt fission. For example,
an increase in the probability of variant stem cell replacement
(from 0.5 to 0.99) alone increases the burden of somatic variants
7-fold. Similarly, promoting the generation of larger patches by
elevated fission rate alone would increase variant burden
2-fold. Together a 14-fold increase by age 60 results (Figure 4B).
Increased fission rates may contribute to field cancerization
effects, whereby an area of histologically normal epithelium con-
taining genetic alterations predisposes to neoplastic develop-
ment (Braakhuis et al., 2003). Such effects have been describedrates for mPAS+ andMAOA– crypts of around 0.68% (95%CI: 0.68 ± 0.15) and
o fission at a rate of 2.15% (95% CI: 2.15 ± 0.27) per year.
Figure 4. Expansion Coefficient Predicts
Age-Related Mutation Burden
(A) Simulation demonstrating mutation rate de-
termines accumulated mutation burden at age 60
years for neutral genes.
(B) Simulated mutation burden of the colon
plotted against patient age for notional genes
sharing a common mutation rate (2 3 106/
mitosis). Plots show neutral outcome (green),
mutation conferring increased PR (0.99) only
(blue), mutation conferring 3-fold increase in rate
of fission only (purple), and mutations conferring
both increased 3-fold fission rate and PR of 0.99
(red) that corresponds to the observed conse-
quence of STAG2 mutation.
(C) Mutant allele frequency data of KRAS(G12D)
mutations from 20 patients determined using
allele-specific competitive blocker (ACB)-PCR
method. Patient data are represented by red
circles. The mean (black line) and 95% CI
(grayed area) of the model is shown. Red dotted
line shows detection threshold. Inset demon-
strating the contribution of fission shows the
predicted average accumulation of KRAS
(G12D) mutant alleles with inferred elevated
(black) and wild-type (blue) fission rates,
respectively.
(D) Boxplot to show the accumulation of KRAS
mutant crypts using both the ACB-PCR method
and targeted amplicon sequencing on a separate
set of patients. >95% ME.
(E) Boxplot to show percentage of KRAS mutant
crypts undergoing fission per year using
both the ACB-PCR and targeted amplicon data.
>95% ME.
(F) Mutant allele frequency data of KRAS muta-
tions from 126 individuals plotted against age. 13
individuals displayed detectable mutations, and
the mean accumulation of mutant allele calculated
using the model is plotted (black line) as well as
the 95% CI. Red dotted line shows detection
threshold.
(G) The calculated patch size of crypts mutant in
respect of KRAS, STAG2, or MAOA/mPAS
shows a significant expansion of KRAS mutant
patches in the human colon following clone fix-
ation.
(H) The average patch size of each clonal mark plotted against the number of fixed clones per colon shows a small number of small clones for MAOA, with similar
patch sizes but higher in frequency for mPAS and STAG2. While for KRAS a small number of large patches is predicted.
(I) Lifetime coefficient of expansion normalized to a neutral mark (mPAS shown) allows comparison of relative advantage.
See also Figure S4.in the context of Crohn’s ileocolitis (Galandiuk et al., 2012) and
sporadic colorectal cancer (Shen et al., 2005).
Clone Dynamics and Kras Mutation
The rate of oncogene activation by single nucleotide mutation is
several orders of magnitude lower than the loss-of-function mu-
tations described here. For example, the G > A transversion that
creates the KRAS(G12D) occurs at a frequency of around 4.0 3
108 per year (Tomasetti et al., 2013). Despite this, KRAS(G12D)
mutations at high allele frequencies (mutant allele frequency
[MAF]) have been described in the normal mucosa including
those of patients not known to have cancer (Dieterle et al.,
2004; Kraus et al., 2006; Parsons et al., 2010).We sought to iden-tify the changes in stem cell behaviors that could explain such
high MAFs.
Initially, we considered the data from one study employing a
sensitive competitive PCR-based method that described a
MAF of around 1.44 3 104 (1/3,500 epithelial cells) for
KRAS(G12D) mutation in the normal mucosa of 20 patients
(Table S3) (Parsons et al., 2010). The stem cell behaviors giving
an optimal fit to the data show that mutation and intracryptal
fixation rates cannot explain the large range of KRAS MAFs,
which requires a 10-fold increase in rate of lateral expansion of
pre-existing clones (Figure 4C).
In validation, we performed targeted sequencing analysis to
detect all activating mutations at KRAS for codons 12/13 onCell Stem Cell 22, 909–918, June 1, 2018 915
188 individuals. Sections from 13 of 126 patients had detectable
MAFs in range of 0.2%–1.8% with an estimated sensitivity of
detection of 103. Inference of the optimal values for DCfix and
fission rate gave values similar to those derived from the Parsons
dataset above (Figures 4D-4F) and confirm that the observed
data can only be explained by a 10-fold increase in the lateral
expansion of KRAS mutant crypts. To explore how clone sizes
change subsequent to clone fixation, simulations were run using
the 10-fold elevated fission rate of 7% per annum to show the
average patch size obtained over 60 years (Figure 4G). The
mutational burden results from the extensive expansion of a
small number of somatic clones in contrast to the more modest
expansion of the loss-of-function clonal marks described earlier
(Figure 4H). Elevated fission rates for KRAS(G12D) resulting in
enlarged multicrypt patches have been described for murine
crypts (Snippert et al., 2014).
Ranking Advantage Conferred by Gene-Specific
Mutation
MAFs for different genes do not themselves convey whether
selective advantage is conferred, as they largely depend on mu-
tation rate. By normalizing for mutation rate and describing the
combined effects of intra-crypt dynamics and subsequent
fission over time, a quantitative measure of selective advantage
can be extracted that allows different mutation events to be
directly compared (Figure 4I). Thus, KRAS(G12D) and STAG2
mutations have an average lifetime expansion coefficient (Cexp)
that is 155- and 13-fold greater than neutral mutations, respec-
tively (Figure 4I).
DISCUSSION
Previous attempts to model the rate of fixation of somatic muta-
tions in human colonic epithelium have recognized the need to
consider physiological stem cell turnover in determining the
probability of fixation (Araten et al., 2005; Kang and Shibata,
2013; Tomasetti and Vogelstein, 2015;Wu et al., 2016; Tomasetti
et al., 2017). However, the parameters for crucial metrics such as
number of functional stem cells and the frequency of stem cell
replacement have been lacking. In addition, there has been no
consideration of how mutational burden is additionally dictated
by crypt fission that allow lateral spreading of variants beyond
individual crypts. Together these factors have prevented bench-
marking of how age-related mutation burden arises within the
colonic epithelium.
The dynamics of clone expansion resulting in monoclonality
of human colonic crypts is notably longer than in mouse, taking
several years. The precise cellular behaviors that underpin
these dynamics are unclear. A paucity of data on stem cell
cycle times for the human epithelium makes relating stem cell
replacement to the frequency of cell division impossible. In
addition, observations in the mouse show that cells positioned
lower (center) and higher (border) with respect to the crypt
base have different self-renewal probabilities but also
frequently exchange between these positions (Ritsma et al.,
2014). Thus, the overarching neutral drift dynamic that we
and others have described is the resolved behavior of the total
stem cell population (Lopez-Garcia et al., 2010; Snippert et al.,
2010; Kozar et al., 2013). Given the larger size of the human916 Cell Stem Cell 22, 909–918, June 1, 2018crypt, such reciprocal exchanges may be more complex, and
this is likely to contribute to the slow dynamics of monoclonal
conversion.
For neutral mutations, the cumulative colonic MAF scales
directly to mutation rate. However, understanding the muta-
tional burden associated with biased behaviors requires a
quantitative description of the normal processes that are sub-
verted. Frequent loss-of-function mutations can reach high
proportions just by impacting on stem cell replacement pro-
cesses within the crypt. For example, STAG2-deficient stem
cells are advantaged in the process of intra-crypt competition
and in the subsequent expansion beyond the crypt. It follows
that expansions of mutant epithelium arise as the first process
increases the numbers of STAG2-deficient crypts available for
subsequent fission events.
Around half of the somatic mutations present in colorectal
cancers are thought to arise in the epithelium before oncogenic
transformation (Tomasetti et al., 2013). The expansion of KRAS-
activating mutations to generate large patch sizes lends itself to
this outcome and demonstrates how powerful oncogenes may
actively contribute to tumor development through a field cancer-
ization effect. As shown here, this outcome can be described
knowing only the rate of mutation and the final MAF.
Here by benchmarking and integrating the relative contribu-
tions of mutation rate and cell renewal/expansion processes in
dictating age-related mutational burden, we provide a means
to express the advantage conferred by gene specific mutations.
This will allow different mutations to be compared and ranked
for advantage within a common framework irrespective of the
specific cellular mechanism by which it is conferred. Practically,
these benchmarks define the nature and window of opportunity
for chemoprevention to limit expansion of pro-oncogenic muta-
tion and thereby limit cancer risk.STAR+METHODS
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Antibodies
Mouse monoclonal anti-MAOA Santa Cruz Biotechnology Sc-271123; RRID: AB_10609510
Rabbit polyclonal anti-MAOA Sigma HPA059299; RRID: AB_2683970
Goat polyclonal anti-STAG2 LifeSpan BioSciences LS-B11284; RRID: AB_2725802
Rabbit polyclonal anti-STAG2 Sigma HPA002857; RRID: AB_1079861
Biological Samples
Normal human colon FFPE blocks Addenbrooke’s Hospital
Cambridge and Norfolk and
Norwich University Hospital
Ethical approval 06/Q0108/307
and 08/H0304/85
Critical Commercial Assays
QIAamp DNA FFPE tissue kit QIAGEN 56404
Deposited Data
Human reference genome NCBI
build 38, GRCh38.p7
Genome Reference Consortium https://www.ncbi.nlm.nih.gov/
projects/genome/assembly/grc/human/
KRAS amplicon sequencing data
(Illumina)
This paper NCBI Study Accession SRP139051
Oligonucleotides
Primer Kras Exon 2 forward: ACACT
GACGACATGGTTCTACA-GGTGGA
GTATTTGATAGTGTATTAACC
This paper N/A
Primer Kras Exon 2 reverse: TACGG
TAGCAGAGACTTGGTCT-TAGCTGT
ATCGTCAAGGCAC
This paper N/A
Software and Algorithms
PANDAseq 2.11 Masella et al. 2012 https://github.com/neufeld/pandaseq/
releases
Frequency of nucleotide calculation
PERL scripts
This paper https://github.com/keke05/KRAS-sequencing/blob/
bd775fc005f89198116a8be97531bd9ec5f5f5ca/
NUCLEOTIDE_COUNT_FOR_HASH.pl
https://github.com/kemp05/KRAS-sequencing/
blob/bd759fc005f89198116a8be97531bd9ec5f5f5ca/
HASH_3.pl
Image segmentation of crypts and clones:
DeCryptICS algorithm
Manuscript in preparation https://github.com/MorrisseyLab/DeCryptICS
Zegami image collection management N/A https://zegami.com/
Google maps pathology viewer N/A https://iime.github.io/virtualmicroscope/
Crypt stochastic drift software: CryptDriftR Manuscript in preparation https://github.com/MorrisseyLab/CryptDriftRCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Douglas
J. Winton (doug.winton@cruk.cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human tissue
Normal colon tissue samples were collected from both Addenbrooke’s Hospital Cambridge and Norfolk and Norwich University
Hospital under full ethical approval (06/Q0108/307 and 08/H0304/85 respectively) according to UK Home Office regulations. A totalCell Stem Cell 22, 909–918.e1–e8, June 1, 2018 e1
of 187 patients were included in the studywith an age range of 8-93 years (Table S1). Colectomy specimenswere fixed in 10%neutral
buffered formalin and from areas of tissue clear of any disease, mucosal sheets were stripped from the specimens and embedded en
face in paraffin blocks.
METHOD DETAILS
Mild PAS (mPAS) staining
From each sample 5 um sections were cut and mounted onto charged slides. Sections were de-waxed and rehydrated before
washing in 0.1 M Acetate buffer pH 5.5 at 4 degrees for 5 minutes. Sections were then oxidised in 1 mM sodium periodate buffer
at 4C for 10 minutes before washing in 1% glycerol for 5 minutes. Three washes were performed in ultra-pure water for 5 minutes
in total before sections were stained in Schiff’s reagent for 15 minutes. Sections were washed again in ultra-pure water before
counter-staining in Mayer’s Haematoxylin for 40 s. Finally sections were washed again in ultra-pure water, blued briefly in tap water
before rinsing in ultra pure water prior to dehydration, clearing and mounting in DPX.
Image segmentation and mPAS clone detection
Sections from all blocks were stained using mPAS and manually viewed to determine stain quality. Each section was scanned using
Aperio software and an image analysis algorithm was devised that identified the number of crypts and the position of mPAS+ clones
within each stained section (Figure S1). In order to be confident that patients included were informative heterozygotes, an inclusion
criterion of > 7000 crypts and at least one sporadic clone detected were set.
Algorithm overview
The aim of the image processing was to both find rare clones (1 in 10,000 crypts) highlighted by the chosen clonal mark, as well as
identify all crypts along with their sizes and shape parameters. The tissue images are gigapixel in size, typically of the order of
50,000 3 50,000 pixels.
Briefly, the algorithm first splits the image into smaller tiles of size 20,000 3 20,000, it then employs color deconvolution on the
images (Ruifrok and Johnston, 2001) to separate the image into a clonal mark channel and a nuclear channel. Using the nuclear chan-
nel it uses morphology operations to identify a number of candidate crypts and then applies a model based classification step to
select the true crypts (Figures S1A and S1B). The algorithm has been constructed so as to be robust to the variability in staining in-
tensities and crypt morphologies observed within and between slides, and while dependent on the quality of the slide, typically iden-
tifies95% of crypts and makes around5% false positives. It was programmed in python using opencv (Bradski, 2000), openslide
(Goode et al., 2013) and Vips (Martinez, 2005) as its image processing libraries.
Pipeline and quality control
Single cell clones are often small and faint, which makes it hard for the algorithm to distinguish them from small artifacts from the
staining process. In order to improve the quality of the data we included all detected clones regardless of size and stain intensity
and introduced a manual quality control stage. The algorithm was altered to produce an image list of candidate clones ordered
by stain intensity and clone size, along with a filled-in spread sheet for manual QC adjustments.
All the outputs were set up to be visualized from a web-browser (Figure S1). Every analyzed slide had associated to it a fully an-
notated slide image that could be visualized using Google maps (https://github.com/evildmp/VirtualMicroscope) (Figure S1D), a
Google-docs spread sheet with the detected clones (Figure S1E) and a web-based image list with the detected clones (Figure S1F).
In order to manage the collections of 1,000 slides we used Zegami [https://zegami.com/] https://zegami2016.molbiol.ox.ac.uk/
crypt_1 (Figure S1G).
Tissue block viewer
The estimation of the mutation rate requires scoring transit amplifying (TA) clones. To find TA clones crypts were tracked in 3D. Serial
sections of a tissue block were analyzed individually as described above. Tissue sections can rotate as they are placed on the slide,
which means that images from serial sections do not always align. We developed a Block Viewer tool that takes all slides from the
same block, aligns them and highlights the QCed clones. The viewer shows zoomed out images of two tissue sections next to each
other with the detected clones highlighted. A slider allows moving through the block sections. The sections are clickable showing
zoomed in versions of the clicked region for both tissue sections, allowing the same crypt to be visualized in high resolution through
the block (Figure S2A).
The tool works by first taking a heavily down-sampled version of the image and applying opencv’s orbmethod to detect key points.
The key points are then used to find the rotation and translation required to align the images via RANSAC fitting. When clicking on the
zoomed out and rotated version of the image we undo the transformation, extract the correct area of the image and transform again
for the zoomed in coordinate system. We found that 80%–90% of images could be aligned this way. In general, the sections that
failed were cases where the sections were very far apart and therefore looked very different.
Estimating the mutation rate for the mPAS clonal mark
As described in Kozar et al., (2013) it is possible to infer the mutation rate using clones arising in the TA compartment. The estimation
is very simple and requires calculating the ratio of TA clones scored in tissue section over the total number of cells scored. Using the
clones found from the algorithm with the block viewer we scored the TA clones. Marked mPAS+ cells were compared across
matched sections. Each mPAS+ clone was manually scored to identify and record those cases where the mPAS positivity wase2 Cell Stem Cell 22, 909–918.e1–e8, June 1, 2018
not part of a larger pre-existing clone. In order to calculate the total number of goblet cells informative for mPAS, Alcian blue staining
was performed, this enabled the average number of goblet cells per crypt area to be calculated and was used to provide cellular
values when calculating the mutation rate (Figure S2). To estimate the number of goblet cells scored, we used the area of the crypts
in these sections to estimate the goblet cells for each crypt. To be able to map the area of the crypts to the number of goblet cells we
generated a separate dataset where we manually scored goblet cells stained by Alcian blue as well as the corresponding crypt area
for 274 crypts of a range of sizes and from 14 different tissue slides (Figures S2B–S2D). Using a non-linear spline regression, we used
this dataset to derive a mapping from crypt area to number of goblet cells.
Evaluation of X-linked genes for clonal analysis
Genes encoded on the X chromosome and subject to X-inactivation were evaluated as potential clonal marks with 111 genes of
which the encoded protein gave strong epithelial staining according to the Human Protein Atlas (HPA) annotations. Of these 20
were selected as showing consistent staining intensities across cell types and throughout the epithelium. Eight of them were
screened as potential clonal marks by IHC staining of large area sections of at least 25 aged individuals (> 70 years) and a minimum
of 70K crypts (Table S2).
Immunohistochemistry
Sections of 5 umwere cut from formalin-fixed paraffin-embedded samples onto charged slides. Sections were de-waxed and re-hy-
drated followed by heat-induced epitope-retrieval using 10 mM Tri-sodium Citrate buffer pH6.0. Sections were blocked in 3% H2O2
in methanol and subsequently blocked in 10% Donkey Serum for 30 minutes. Slides were then incubated with anti-MAOA or anti-
STAG2 antibodies (MAOA: mouse monoclonal, Santa Cruz Biotechnology and Rabbit polyclonal, Sigma, STAG2: goat polyclonal,
LifeSpan BioSciences and Rabbit polyclonal, Sigma) overnight at 4C. Sections are incubated with biotin-SP-conjugated AffiniPure
donkey anti-mouse or anti-goat, Jackson ImmunoResearch, both 1:500 in PBS-T) for 40 minutes at room temp followed by incuba-
tion with Vectastain Elite ABC reagent (Vector Laboratories) for 40 minutes. This was followed by immunoperoxidase detection
using a liquid DAB + substrate chromogen system (Dako). Sections were then counterstained in hematoxylin before dehydration,
clearing and mounting.
Targeted amplicon KRAS sequencing
Genomic DNAwas extracted from FFPE sections using a QIAampDNA FFPE tissue kit (QIAGEN-56404) according tomanufacturer’s
instructions. gDNA template was PCRamplified in duplicate for each sample (NEBPhusion DNApolymerase, HF buffer, 2mMMgCl2,
200 mMeach primer, 500 nMdNTPs). Forward and reverse gene specific primers fusedwith FluidigmCorporation barcoding CS1 and
CS2 adaptor sequences (forward - ACACTGACGACATGGTTCTACA-GGTGGAGTATTTGATAGTGTATTAACC and reverse - TACG
GTAGCAGAGACTTGGTCT-TAGCTGTATCGTCAAGGCAC) were used. The resulting amplicon comprised 159bp of KRAS sequence
encompassing codons 12 and 13. Amplicons were diluted and re-amplified with Fluidigm barcoding primers (incorporating a unique
sample barcode and Illumina P5 and P7 adaptor sequences), pooled and subjected to 150 bp paired end sequencing on an Illumina
MiSeq platform.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis of clone data
A general note on simulations and the mathematical model
Throughout the manuscript we have made use of a mathematical model (described below) that models the acquisition of a mutation,
the competition of the mutant stem cell with the other stem cells and, once fixed, the fission of the mutant crypt.
Additionally we challenge the model with two more complex scenarios to study whether more complexity is warranted. We do this
using simulations that encode the same assumptions as the mathematical model but with additional behaviors. Specifically, we
check the effect of fusion on patch size and the effect of double hits on the clonal dynamics.
The implementations of these two simulations are very different as, in order to simulate fusion, one has to simulate the spatial dy-
namics of the clone and surrounding crypts (a monoclonal crypt can fuse with another monoclonal crypt or to an unlabelled crypt
leading to a partial), whereas the double hit simulations require just one crypt to be modeled but require tracking the individual cells
and how many mutations each one has.
All the simulations were coded in python using the numba library for speed.
Statistical inference
All data fitting was done using the statistical models described in the fitting sections below and sampled from using Rstan (Carpenter
et al., 2017). Rstan was run using 5 chains of 10,000 iterations and a thinning of 5. The default parameters were used for the sampler,
though where necessary, the models were reparamertised and run parameters adapted. Convergence was checked using the scale
reduction factor provided by Rstan.
Within the main text estimates are presented as credible intervals (CI) or alternatively as a margin of error (ME) expressed as a me-
dian and 1.96 times the standard deviation of the posterior. For cases where new parameters, are calculated that are functions of the
inferred parameters we apply the function to all the posterior mcmc samples and present the median and 1.96 times the standard
deviation of the transformed samples.Cell Stem Cell 22, 909–918.e1–e8, June 1, 2018 e3
For some of the cases below, Gaussians were used tomodel the population variability of a parameter defined in the [0, 1] range, for
these cases the range of the parameter was specified in Stan.
Statistical model for TA clones
Patients were selected based on tissue block size that so as to be able to estimate a mutation rate per block. In some cases we had
several such blocks for the same patient, which we used within the statistical model to estimate the within patient variability and
experimental error. A hierarchical model was used as follows, assuming wemeasure ki;b TA clones for patient i in block b, the number
of goblet cells measured is Gi;b and the mutation rate for patient i is ai the counts are distributed as
qi;b  Normalðai;serrorÞki;b  Binomial

Gi;b;qi;b

We calculate the distribution of the mutation rate in the patient population as
ai  Normalðma;saÞ
The priors used were:
ma  Betað1=2;1=2Þ
sa  Betað1=2;1=2Þ
serror  Betað1=2;1=2Þ
Continuous labeling of a neutral mutation
Herewe describe the continuous labelingmodel that can be found in Kozar et al., (2013). It has been shown that crypts aremaintained
by an equipotent population of stem cells at the crypt base that constantly replace each other in a stochastic fashion (Lopez-Garcia
et al., 2010; Snippert et al., 2010). The equations that govern the change in clone size with time assume we start tracking the progeny
of a clone of size 1 stem cell at t = 0. The probability of a crypt having clone of size n (for 0 < n < N) at time t is:
PnðtÞ= 2
N
XN1
m= 1
sin
pm
N

sin
pmn
N

e4l sin
2ðpmN Þt
Here n is the number of stem cells that make up the clone, N is the total number of stem cells in the crypt base and l is the rate of stem
cell replacement. For the probability of the clone being of maximum size, i.e., a monoclonal crypt:
PNðtÞ= 2
N
XN1
m= 1
ð1Þm+ 1 cos2
pm
2N

1 e4l sin2ðpm2NÞt

For our case if we are tracking mutationally tagged clones. If we take the mutation rate to be a the rate at which a crypt will get a
mutationally activated clone will be
k=alN
If we write down the stochastic master equation for this:
dQ0
dt
=  kQ0
dQ1
dt
= kQ0
We can solve and get
Q1ðtÞ=

1 ekt
As the mutation rate is very low we can use a Taylor expansion to get
Q1ðtÞzkt
New clones of size one stem cell are appearing continuously over time, assuming the mutation has no effect on the stem cell dy-
namics, the clone size will evolve according to the equations above. To model the probability of clone size over time we can use
the integral
CnðtÞ=
Z t
0
dQ1
dt
ðtÞPnðt  tÞdt
Which assumes that the clones that disappear due to stem cell competition have a negligible effect on Q0.e4 Cell Stem Cell 22, 909–918.e1–e8, June 1, 2018
Solving for the non-monoclonal clones and pooling them to get the partial clone prediction we get:
Cpartial =a
NðN 1Þ
2
 a
2
XN1
n;m= 1
sin
pm
N

sin
pmn
N

sin2
pm
2N
 e4lsin2ðpm2NÞt
For the monoclonal clones we get
Cmonoclonal =alt  a
2
XN1
m= 1
ð1Þm+ 1
tan2
pm
2N
1 e4lsin2ðpm2NÞt
The effect of the exponential term is quickly lost, leading to a constant term for the partials and a linear function for the monoclonals.
Continuous labeling of a non-neutral mutation
Vermeulen et al., (2013) showed that certain mutations can affect the clonal dynamics. Furthermore they showed that these altered
dynamics could be parameterized by introducing a replacement probability, PR. The equations for the non-monoclonal and mono-
clonal clones are as follows:
RnðtÞ= 2
N

b
g
1
2
ðn 1ÞXN1
m= 1
km;ne
hmtRNðtÞ= 2b
N

b
g
1
2
ðN 2ÞXN1
m= 1
km;N1
hm

1 ehmt
Where the following shorthand has been used:
g= 2lð1 PRÞ
b= 2lPR
km;n = sin
pm
N

sin
pmn
N

hm = 4
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
gbsin2
q pm
N

+g+ b+  2
ffiffiffiffiffiffi
gb
p
While the drift dynamics are different to the neutral case, the dynamics of the appearance of the initial mutations are the same; there-
fore we can derive the continuous labeling equations in the same way
bCnðtÞ= Z t
0
dQ1
dt
ðtÞRnðt  tÞdt
Which leads to
bCpartialðtÞ= 2k
N
XN1
m;n=1

b
g
1
2
ðn 1Þ
km;n
hm

1 ehmt
bCmonoclonalðtÞ= 2bk
N

b
g
1
2
ðN 2ÞXN1
m= 1
km;N1
hm

t  1
hm

1 ehmt
For the sake of brevity we do not expand the equations, however it is worth noting that much like the neutral mutations, after a short
initial period the monoclonals follow a linear equation and the partials converge to a constant value. For both the neutral and non-
neutral cases the equations are proportional to the mutation rate, meaning that the ratio of the slope of the monoclonal accumulation
over the partials gives a value that is independent of the mutation rate. This can be used as a way of comparing the clonal dynamics
for different mutations.
Fitting the monoclonal clones and partial clones
As the probability of a crypt containing a monoclonal clone at time t is a linear function we fit the following model to the mono-
clonal data:
pi = aiðti  t0Þ
kmonoi  BinomialðCi;piÞ
Where kmonoi is the number ofmonoclonal crypts found for patient i,Ci is the number of crypts in the tissue sample, ti is the patient age,
ai is the slope of the monoclonal accumulation for patient i and t0 is the x axis intercept. As we expect the mutation rate to have some
variation between individuals, as well as the drift parameters, we allow each patient to have its own slope, using a hierarchical modelCell Stem Cell 22, 909–918.e1–e8, June 1, 2018 e5
ai  Normalðma;saÞ
The priors on the parameters are as follows
ma  Gamma

102; 102

sa  Gamma

102;102

t0  Normalð0; 10Þ
Note how we are allowing t0 to be negative. While the stem cell dynamics equations suggest that the y-intercept should be negative,
and as such the x-intercept should be positive it is possible that clones might arise during development that would increment the
y-intercept allowing for the x-intercept to become negative. We choose a value that encompasses 20 years to either side of the
origin to allow a wide range of values, however restricting implausible values.
We follow a similar analysis for the partial clones.
kpartiali  BinomialðCi;biÞ
bi  Normalðma;sbÞ
With priors
mb  Gamma

102;102

sb  Gamma

102;102

Effect of crypt fusion on patch size
A recent study has shown that crypts not only undergo fission, where a crypt divides into two crypts, but they can also fuse with a
neighboring crypt thus combining the stem cell pools. The study found that fission and fusion are balanced, both occurring at the
same rate.
At the clonal level fusion can cause amutant crypt to join with a nonmutant producing a partially mutant crypt or twomutant crypts
can join forming a single mutant crypt. This introduces a spatial aspect to the model, which complicates an analytical approach. To
assess the effect of fusion we implement a stochastic simulation algorithm which uses the gillespie algorithm. The simulation models
a field of crypts and implements the mutation process, stem cell drift, fission and fusion, including the spatial aspects as well as the
two types of fusion events described above.
The simulations showed that relative patch size is dominated by fission, with fusion having a very modest effect (Figure S4).
Crypt fission and mutation burden
We model crypt fission as a Yule-Furry pure birth process. The general solution to this process is:
bFnðtÞ=

n 1
n n0

ern0t

1 ern0tnn0
Where n0 is the patch size at time t = 0 and r is the rate of crypt fission. In order to calculate the patch size distribution over time given
that the monoclonal crypts appear following a known function we can use a similar calculation as for the continuous labeling equa-
tions. We fix n0 = 1 and integrate:
FnðtÞ=
Z t
0
dCmonoclonal
dt
ðtÞ bFnðt  tÞdt
Ignoring the exponential term from Cmonoclonal which has a negligible effect, we find
FnðtÞ=DCmonoclonalð1 e
rtÞn
rn
Here DCmonoclonal is the slope of the monoclonal accumulation. This equation also holds for mutations that affect clonal drift. We use
this equation to estimate the mutant burden per million crypts used in the main text:
BðtÞ= 106
XN
n= 1
nFnðtÞ
Relative expansion coefficient
In order to derive a metric for each mutation that allows comparison of the ability of the mutation to spread through the tissue we
calculate the burden of a mutation averaged over the lifetime of the individual. We then calculate the ratio of average burden between
a given mutation and the wild-type parameters. By fixing the mutation rate to the same value for both average burden estimates, the
mutation rate disappears from the ratio.
Imutant =
1
100
Z 100
0
BmutantðtÞdt
1
100
Z 100
0
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We refer to this value as a relative expansion coefficient (Cexp). The values used in themain text were calculated numerically using the
burden equation described in the previous section.
Statistical model for patch sizes
The patch size equation depends on the slope of the monoclonals, which we can infer from themonoclonal data. However in order to
minimize the uncertainty in the crypt fission estimation, we calculate the equation for the relative distribution of patch sizes that does
not depend on the slope of the monoclonals:
fnðtÞ= FnðtÞ
CmonoclonalðtÞ=
ð1 ertÞn
rnt
This is the same equation used by Baker et al., (2014). We also apply a correction for the confounding effect of two unrelated clones
randomly being found next to each other and counted as a patch. If a tissue sample has k clones, C crypts and each crypt has d
neighboring crypts the proportion of clones that form random doublets will be:
D=
Xk1
i = 1
d
k
i
C izd
k  1
2C
We do not calculate the probability of patches larger than two appearing due to chance as the probability of these events will be
negligible. When fitting the model to the data we add D to f2 and subtract D from f1.
As a first step for the fitting we filter samples with no clones as we are fitting the relative patch size. Again we use a hierarchical
model to account for patient-to-patient variability. If gi is a vector of measured patch sizes, ti is the age of the patient, ri is the fission
rate for that patient we have
gi  Multinomialðfðri; tiÞÞ
ri  Normal

mr;sr

Where f is the vector of probabilities of each patch size calculated from the fission equation and corrected as specified above. The
priors used for the population parameters are
mr  Gamma

102; 102

sr  Gamma

102;102

Sequential mutations
The mutation of STAG2, a gene that when mutated is associated with chromosomal instability, was found to have a biased behavior.
The fact that STAG2 is associated to chromosomal instability raises the question of whether the biased behavior is the consequence
of further unmeasured mutations enabled by the chromosomal instability or directly caused by STAG2. To find which might be the
most likely scenario we run simulations where we assume that a first neutral mutation raises the mutation rate of a second mutation
that biases drift.
The simulation uses the Gillespie Algorithm to simulate a single crypt with N stem cells, each of which starts with no mutations and
can acquire a first mutation which doesn’t change the drift dynamics, however the mutant cells now have an enhanced probability of
a second mutation which does lead to a bias. The simulation produces two outputs, the monoclonal and partial crypts for the first
mutation, regardless of whether or not they have the secondmutation (this would be what wemeasure with STAG2) and also outputs
the full and partial crypts with both mutations (as you can’t have mutation 2 without 1).
If we can only measure mutation 1, as happens with STAG2, in order to see altered dynamics caused by mutation 2 the mutation
has to occur while mutation 1 has not yet become monoclonal, otherwise we would measure no difference (Figures S3H and S3I).
Analysis of KRAS sequencing data
Analysis of raw data
Corresponding forward and reverse reads were combined into a single consensus sequence using PANDAseq 2.11 with default op-
tions (Masella et al. 2012). Amplicon sequences were removed if they did not begin and end with the forward and reverse gene spe-
cific primer sequences respectively and/or were incorrect overall length (> 164 bp). Both read number (R1000) and FFPE section
quality (R1000 crypts identified in a serial section) were used to filter data resulting in 126 patients being processed for further anal-
ysis. The frequency of all four nucleotides at all amplicon positions was calculated for each sample using a custom PERL script
(NUCLEOTIDE_COUNT_FOR_HASH.pl). The resulting flat file was processed by HASH_3.pl to calculate the percentage frequency
for every position/nucleotide for each sample and then the mean frequency and st.dev. of all samples, on a given sequencing run, for
each particular position/nucleotide. Mutations were called if a variant nucleotide exceeded either; 4x themean allele frequency or the
mean allele frequency + 3.209 st.dev., and there were a minimum of 10 variant reads (the mean read depth per sample was 10535
[±6002 st.dev.]). Both replicates of a sample had to be called with the same mutation for the sample to be considered mutated. The
actual MAF for subsequent use was calculated by subtracting the mean allele frequency for that position/nucleotide.
Statistical model for patch size estimation
From this analysis sections from 13 of 126 patients had detectableMAF in range of 0.2%–1.8%with an estimated sensitivity of detec-
tion of 103 (Table S3). To analyze this allele frequency data we first convert it to mutation burden. To do so we note that if in a sectionCell Stem Cell 22, 909–918.e1–e8, June 1, 2018 e7
of tissue we have mmutant crypts, C total crypts and n cells per crypt the ratio of mutant copies of a gene to total copies of the gene
will be
fallele =
mn
2Cn
which means that the allele frequency is half of the mutation burden.
In order to model this data we can use the equation for patch sizes derived earlier, namely
FnðtÞ=DCmonoclonalð1 e
rtÞn
rn
Which gives us the probability of finding a patch of size n at age t. Themodel has two parameters the fission rate r and themonoclonal
accumulation rate DCfix. These are the two parameters we wish to infer from the data.
The statistical fitting must account for the fact that there is a detection limit below which there may be clones but we cannot detect
them. This threshold is very different for the two data types we are fitting. We set up the statistical model so that if the mathematical
model predicts that there should be a patch but wemeasure none, as long as it is below the specified detection threshold, it does not
penalise the fit.
We first take themeasured allele frequency and convert them tomutation burden, we then use the number of crypts from that sam-
ple to convert the burden into patch size. For the amplicon sequencing we know how many crypts we have in the sample from the
image processing. For the ACB-PCRwe know that the amount of DNA used is 300,000 copies sowe estimate the number of crypts to
be 150,000.
We cannot directly use the patch size equation aswe need to accommodate the fact that we have a range of possible patch sizes of
which each patient will only have one, also the probability of not detecting a patch will need to be calculated depending on the values
of the parameters.
We model each patient sample as a multinomial with three categories, probability that a crypt has no detectable clone q0, prob-
ability q1 that we see a patch of size n (where n is the observed patch size) and q2 the probability of all the remaining patch sizes, used
to normalize the multinomial q2 = 1 ðq0 + q1Þ. We calculate q0, which incorporates the detection threshold as
q0 =
Xnlimit
n= 0
FnðtÞ
Here nlimit is the largest patch size that would not be detected. We calculate the probability of no clone with
F0 = 1 DCmonoclonalt
The likelihood will be
ni  MutinomialðqÞ
Where q is the vector described above and ni is a vector of 3 counts for patient i: total crypts, zero or one if there is a patch and 0 for
the third category.
The priors used for the two parameters are
r  half­normalð0;0:5Þ
DCfix  half­normal

0; 104

For the results of the two datasets to be comparable we need to scale DCfix by the number of mutations we look at. In the case of
ACB-PCR we just look at one, whereas with the targeted sequencing we look at 12 possible mutations.
DATA AND SOFTWARE AVAILABILITY
Please refer to theURLs for the following: collection of slides stainedwithmPAS, https://zegami2016.molbiol.ox.ac.uk/crypt_1; Google
maps pathology viewer, https://iime.github.io/virtualmicroscope/; image segmentation software DeCryptICS, https://github.com/
MorrisseyLab/DeCryptICS; crypt stochastic drift software CryptDriftR, https://github.com/MorrisseyLab/CryptDriftR; KRAS
sequencing data, NCBI Study Accession SRP139051; and sequence analysis scripts, https://github.com/kemp05/KRAS-sequencing/
blob/bd759fc005f89198116a8be97531bd9ec5f5f5ca/NUCLEOTIDE_COUNT_FOR_HASH.pl and https://github.com/kemp05/KRAS-
sequencing/blob/bd759fc005f89198116a8be97531bd9ec5f5f5ca/HASH_3.pl.e8 Cell Stem Cell 22, 909–918.e1–e8, June 1, 2018
